



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

3 September 2020

ANNOUNCEMENT




Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

OPERATIONS UPDATE ON FORTACIN™



The directors (the “**Directors**” or the “**Board**”) of Regent Pacific Group Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) wish to inform the shareholders of the Company and potential investors of the following update in respect of its operations in relation to Fortacin™.



Further to the last operations update issued by the Company on 5 August 2020 and the preliminary announcement on its interim results for the six months ended 30 June 2020, issued on 24 August 2020, the Directors are pleased to inform shareholders that Recordati S.p.A. (“**Recordati**”) has received approval from the European Commission on 27 August 2020 that the marketing authorisation for Fortacin™ be changed to “Over-the-Counter” (“**OTC**”) status from prescription (“**Rx**”). As previously stated, the OTC switch is a move designed to significantly increase sales and consequently uplift the royalty payments to the Group. Recordati has mentioned that it would look to start the OTC launch from January 2021 provided that it (i) has received any national approvals that are required (if any) and (ii) Pharmaserve (North West) Limited (“**PSNW**”), the manufacturer, can meet the anticipated increased demand and that the COVID-19 pandemic does not further complicate or impede the planned launch. Recordati, PSNW and the Group are looking into options at scaling up



the manufacturing process to meet the anticipated demand in OTC with the aim of manufacturing approximately 50,000 units per batch order and reducing the risk of supply chain shortage and unreliability.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Executive Director

Directors of the Company:

James Mellon (*Chairman*)*
Jamie Gibson (*Chief Executive Officer*)
David Comba#
Julie Oates#
Mark Searle#
Jayne Sutcliffe*

* *Non-Executive Directors*

Independent Non-Executive Directors

Hong Kong, 3 September 2020